- Home
- GRABW vs GALT Comparison
GRABW vs GALT Comparison
Compare GRABW & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRABW | GALT |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | Singapore | United States |
| Employees | 11267 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 261.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GRABW | GALT |
|---|---|---|
| Price | $0.30 | $4.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 54.7K | ★ 803.2K |
| Earning Date | 02-21-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,686,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.65 | N/A |
| 52 Week Low | $0.15 | $0.94 |
| 52 Week High | $0.59 | $7.13 |
Technical Indicators
Market Signals| Indicator | GRABW | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 38.47 | 34.77 |
| Support Level | $0.29 | $3.90 |
| Resistance Level | $0.32 | $4.19 |
| Average True Range (ATR) | 0.04 | 0.60 |
| MACD | -0.00 | -0.22 |
| Stochastic Oscillator | 37.35 | 14.58 |
Price Performance
Historical ComparisonAbout GRABW Grab Holdings Limited Warrant
Founded in 2012, Grab provides ride-sharing services, food and grocery delivery, and financial services (payments, consumer loans, and enterprise offerings) in eight Southeast-Asian countries through its mobile platform. The company partners with merchants and riders, connecting them with consumers while charging commission to both sides. Grab has a leading market share in and derives 89% of its revenue from its core businesses, ride-sharing and food delivery. Singapore, Indonesia, and Malaysia contributed more than 70% of revenue in 2024. Grab's main competitors in Southeast Asia are Line Man and Goto. Its financial services business is still in its nascent stage and provides minimal revenue currently. The company now also generates advertising revenue.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.